Your browser doesn't support javascript.
Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race.
Berrian, Jennifer; Liu, Ying; Ezenwajiaku, Nkiruka; Moreno-Aspitia, Alvaro; Holton, Sara J; Toriola, Adetunji T; Colditz, Graham A; Housten, Ashley J; Hall, Lannis; Fiala, Mark A; Ademuyiwa, Foluso O.
  • Berrian J; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Liu Y; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Ezenwajiaku N; University of Miami, Coral Gables, Florida, USA.
  • Moreno-Aspitia A; Mayo Clinic, Jacksonville, Florida, USA.
  • Holton SJ; Mayo Clinic, Jacksonville, Florida, USA.
  • Toriola AT; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Colditz GA; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Housten AJ; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Hall L; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Fiala MA; Washington University School of Medicine, St. Louis, Missouri, USA.
  • Ademuyiwa FO; Washington University School of Medicine, St. Louis, Missouri, USA.
Cancer Med ; 2022 Nov 20.
Article in English | MEDLINE | ID: covidwho-2251985
ABSTRACT

PURPOSE:

To determine if the COVID-19 pandemic has further exacerbated racial disparities in late-stage presentation of breast, colorectal, lung, and prostate cancers.

METHODS:

We conducted a registry-based retrospective study of patients with newly reported diagnoses of breast, colorectal, lung, and prostate cancers between March 2019-June 2019 (pre-COVID-19) and March 2020-June 2020 (early-COVID-19). We compared the volume of new diagnoses and stage at presentation according to race between both periods.

RESULTS:

During the study period, a total of 3528 patients had newly diagnosed cancer; 3304 of which had known disease stages and were included in the formal analyses. 467 (14.1%) were Blacks, and 2743 were (83%) Whites. 1216 (36.8%) had breast, 415 (12.6%) had colorectal, 827 (25%) had lung, and 846 (25.6%) had prostate cancers, respectively. The pre-COVID-19 period included 2120 (64.2%), and the early-COVID-19 period included 1184 (35.8%), representing a proportional 44.2% decline in the volume of new cases of breast, colorectal, lung, and prostate cancers, p < 0.0001. Pre-COVID-19, 16.8% were diagnosed with metastatic disease, versus 20.4% early-COVID-19, representing a proportional increase of 21.4% in the numbers of new cases with metastatic disease, p = 0.01. There was a non-significant proportional decline of 1.9% in Black patients diagnosed with non-metastatic breast, colorectal, lung, and prostate cancers early-COVID-19 (p = 0.71) and a non-significant proportional increase of 7% in Black patients diagnosed with metastatic disease (p = 0.71). Difference-in-difference analyses showed no statistically significant differences in metastatic presentation comparing Black to White patients.

CONCLUSION:

While we identified substantial reductions in the volume of new cancer diagnoses and increases in metastatic presentations due to the COVID-19 pandemic, the impact was similar for White and Black patients.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Language: English Year: 2022 Document Type: Article Affiliation country: Cam4.5439

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study Language: English Year: 2022 Document Type: Article Affiliation country: Cam4.5439